New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting

Date : 11/04/2019 @ 1:00PM
Source : Business Wire
Stock : Horizon Therapeutics Public Limited Company (HZNP)
Quote : 31.89  -0.34 (-1.05%) @ 1:00AM
After Hours
Last Trade
Last $ 31.89 ◊ 0.00 (0.00%)

New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting

Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart

2 Months : From Oct 2019 to Dec 2019

Click Here for more Horizon Therapeutics Pub... Charts.

-- Data to be presented from in-practice clinician case series on novel immunomodulation strategy --

Horizon Therapeutics plc (Nasdaq: HZNP) today announced multiple presentations that will highlight the serious, systemic effect of urate deposition and will inform strategies to optimize treatment of uncontrolled gout through immunomodulation during the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta.

Presentation details:

  • Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase In Uncontrolled Gout Patients in a Community Rheumatology Practice
    • Abstract: 1236, J. Albert
    • Monday, Nov. 11, 2019; 9 – 11 a.m. ET
  • Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
    • Abstract: 1231, N. Schlesinger
    • Monday, Nov. 11, 2019; 9– 11 a.m. ET
  • Renal Transplant Complications in Patients with and without Gout
    • Abstract: 335, M. Francis-Sedlak
    • Sunday, Nov. 10, 2019; 9 – 11 a.m. ET

In addition, Horizon will host a presentation featuring Ada J. Kumar, M.D., Horizon associate medical director, on Monday, Nov. 11 at 3:30 p.m. ET in Innovation Theater B, to illustrate the breadth of uric acid crystal’s impact beyond the joints, to multiple other tissues, through historical and advanced imagery.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.

Contacts: Tina Ventura Senior Vice President, Investor Relations Investor-relations@horizontherapeutics.com

Ruth Venning Executive Director, Investor Relations Investor-relations@horizontherapeutics.com

U.S. Media Contacts: Amanda Phraner Associate Director, Public Relations and Social Media media@horizontherapeutics.com

Ireland Media Contact: Gordon MRM Ray Gordon ray@gordonmrm.ie

Latest HZNP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.